Erin Lavelle - Eliem Therapeutics COO VP
| ELYMDelisted Stock | USD 5.02 0.16 3.29% |
Insider
Erin Lavelle is COO VP of Eliem Therapeutics
| Age | 47 |
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
Eliem Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. Eliem Therapeutics' management efficiency ratios could be used to measure how well Eliem Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gregory Russotti | Century Therapeutics | 57 | |
| Peng MD | Pharvaris BV | 46 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| Robyn Sweinhart | Rezolute | N/A | |
| MD MPH | MediciNova | 56 | |
| Luis Borges | Century Therapeutics | 62 | |
| Wim Souverijns | Pharvaris BV | 53 | |
| James McArthur | PepGen | 62 | |
| Michael Gait | PepGen | N/A | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| David MBA | Champions Oncology | 55 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| John CPA | MediciNova | N/A | |
| Michael Diem | Century Therapeutics | 53 | |
| Annick Deschoolmeester | Pharvaris BV | 51 | |
| Anne Lesage | Pharvaris BV | 63 | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| MBA BS | AN2 Therapeutics | 49 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
Eliem Therapeutics Leadership Team
Elected by the shareholders, the Eliem Therapeutics' board of directors comprises two types of representatives: Eliem Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eliem. The board's role is to monitor Eliem Therapeutics' management team and ensure that shareholders' interests are well served. Eliem Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eliem Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
Eliem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eliem Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |